# US 2006/0154864 A1 · Transcript factor and an Akt substrate related to transcriptional action of insulin and applications of same

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2006/0154864 A1
- Document ID: US20060154864A1
- Status: Published application
- Kind: A1
- Application number: 11/288,992
- Filed: 2005-11-29
- Published: 2006-07-13
- Earliest claimed: 1999-11-01
- Assignees: Emory University
- Inventors: Betty Villafuerte
- Web page: https://patentgrep.com/patent/US20060154864A1

## CPC

- C07K 14/4705: {stimulating, promoting or activating activity}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

A transcription factor capable of activating multiple insulin-responsive genes. In one embodiment, the transcription factor includes an NH2-domain containing thirteen epidermal growth factor (EGF)-like repeats proximate to the N-terminus, a solitary calcium-binding EGF-like domain proximate to the C-terminus, and three consecutive fibronectin type III (fn3) domains between the NH2-domain and the EGF-like domain.

## Claims

### Claim 1

A transcription factor capable of activating multiple insulin-responsive genes, comprising:
a. an NH2-domain containing thirteen epidermal growth factor (EGF)-like repeats proximate to the N-terminus;
b. a solitary calcium-binding EGF-like domain proximate to the C-terminus; and
c. three consecutive fibronectin type III (fn3) domains between the NH2-domain and the EGF-like domain.

### Claim 2 (depends on 1)

The transcription factor according to claim 1, wherein the NH2-domain is a sushi domain.

### Claim 3 (depends on 1)

The transcription factor according to claim 1, wherein the three fibronectin type III (fn3) domains form a motif comprising approximately 100 amino acids that can bind to DNA and interacting proteins.

### Claim 4 (depends on 1)

The transcription factor according to claim 1, wherein the NH2-domain comprises at least one of the peptide sequences LSVLS (at amino acid sequence 347-378).

### Claim 5 (depends on 1)

The transcription factor according to claim 1, wherein the NH2-domain comprises at least one of the peptide sequences DRSR (at amino acid sequence 603-606).

### Claim 6 (depends on 1)

The transcription factor according to claim 1, characterized in that the transcription factor binds and transactivates the insulin-response elements of an insulin-like growth factor binding protein-3 and other insulin responsive genes among multiple insulin-responsive genes.

### Claim 7 (depends on 6)

The transcription factor according to claim 6, further characterized in that the transcription factor is a target of insulin signal transduction downstream of the phosphatidylinositol 3′-kinase/protein kinase B (Akt) pathway.

### Claim 8 (depends on 7)

The transcription factor according to claim 7, wherein Akt phosphorylates the transcription factor in vivo.

### Claim 9 (depends on 7)

The transcription factor according to claim 7, wherein Akt phosphorylates the transcription factor in vitro.

### Claim 10 (depends on 1)

A therapeutic agent to mimic or enhance insulin action comprising the transcription factor of claim 1.

### Claim 11

A method of regulating the expression of gene transcription by insulin, comprising the step of using a transcription factor for binding and transactivating the insulin-response elements of an insulin-like growth factor binding protein-3.

### Claim 12 (depends on 11)

The method according to claim 11, wherein the transcription factor comprises:
a. an NH2-domain containing thirteen epidermal growth factor (EGF)-like repeats proximate to the N-terminus;
b. a solitary calcium-binding EGF-like domain proximate to the C-terminus; and
c. three consecutive fibronectin type III (fn3) domains between the NH2-domain and the EGF-like domain.

### Claim 13 (depends on 12)

The method according to claim 12, wherein the NH2-domain is a sushi domain.

### Claim 14 (depends on 12)

The method according to claim 12, wherein the three fibronectin type III (fn3) domains form a motif comprising approximately 100 amino acids that can bind to DNA and interacting proteins.

### Claim 15 (depends on 12)

The method according to claim 12, wherein the NH2-domain comprises at least one of the peptide sequences LSVLS (at amino acid sequence 347-378).

### Claim 16 (depends on 12)

The method according to claim 12, wherein the NH2-domain comprises at least one of the peptide sequences DRSR (at amino acid sequence 603-606).

### Claim 17 (depends on 12)

The method according to claim 12, further comprising the step of using the transcription factor for binding and transactivating the insulin-response elements of at least one insulin responsive gene among multiple insulin-responsive genes.

### Claim 18

A method of regulating the expression of gene transcription by insulin, comprising the step of using sensitin for binding and transactivating the insulin-response elements of an insulin-like growth factor binding protein-3.

### Claim 19 (depends on 18)

The method according to claim 18, wherein sensitin has:
a. a 120 kDa protein under non-reducing conditions; and
b. a 50 kDa transcriptionally active protein after being truncated.

### Claim 20 (depends on 19)

The method according to claim 19, characterized in that insulin transduces its signals to sensitin.

### Claim 21 (depends on 19)

The method according to claim 19, further characterized in that hepatic overexpression of sensitin lowers fasting and post-prandial glucose levels in a living subject with diabetic symptoms through mechanisms that involve decreased hepatic expression of gluconeogenic genes.

### Claim 22 (depends on 19)

The method according to claim 19, further characterized in that sensitin is regulated through phosphatidylinositol 3′ kinase-dependent-phosphorylation and proteolysis, which in turn modulates the subcellular localization and transcriptional activity of the factor.

### Claim 23 (depends on 22)

The method according to claim 22, wherein sensitin is an Akt substrate.

### Claim 24 (depends on 23)

The method according to claim 23, wherein sensitin is phosphorylated by Akt in vivo.

### Claim 25 (depends on 23)

The method according to claim 23, wherein sensitin is phosphorylated by Akt in vitro.

### Claim 26 (depends on 19)

The method according to claim 19, further comprising the step of using sensitin for binding and transactivating the insulin-response elements of at least one insulin responsive gene among multiple insulin-responsive genes.
